Triple administration of osimertinib followed by chemotherapy for advanced lung adenocarcinoma: A case report

doi:10.12998/wjcc.v9.i11.2627

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7419)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series.

Item

Count

PDF

326

WORD

203

HTML

4939

Figures (1-3)

376

Sum=5844

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

591

Download

984

Sum=1575

Apr 16, 2021 (publication date) through Jan 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Apr 16, 2021; 9(11): 2627-2633
Published online Apr 16, 2021. doi: 10.12998/wjcc.v9.i11.2627

Full Size Figure Download Figure

Figure 3 Entire treatment course with variations in carcinoembryonic antigen levels at each visit from the initial treatment to the present. EGFR: Epidermal growth factor receptor; CEA: Carcinoembryonic antigen.

Citation: Hu XY, Fei YC, Zhou WC, Zhu JM, Lv DL. Triple administration of osimertinib followed by chemotherapy for advanced lung adenocarcinoma: A case report. World J Clin Cases 2021; 9(11): 2627-2633
URL: https://www.wjgnet.com/2307-8960/full/v9/i11/2627.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i11.2627